UB Paderborn / Katalog / Suche / in CDI

Screening for Barrett’s esophagus: Ready for prime time or still hard to swallow?

Gastrointestinal endoscopy, 2021-09, Vol.94 (3), p.506-508

2021

Volltextzugriff (PDF)

S386 An Objective Spatialomics Test Standardizes Management Decisions With Potential to Improve Health Outcomes for Barrett’s Esophagus Patients

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e269-e269

2022

Volltextzugriff (PDF)

Risk stratification in Barrett's esophagus patients with diagnoses of indefinite for dysplasia: the definite silver bullet has not (yet) been found

Gastrointestinal endoscopy, 2020-01, Vol.91 (1), p.11-13

2020

Volltextzugriff (PDF)

An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus

The American journal of gastroenterology, 2023-11, Vol.118 (11), p.2025-2032

2023

Volltextzugriff (PDF)

Feasibility Study Utilizing NanoString's Digital Spatial Profiling (DSP) Technology for Characterizing the Immune Microenvironment in Barrett's Esophagus Formalin-Fixed Paraffin-Embedded Tissues

Cancers, 2023-12, Vol.15 (24), p.5895

2023

Volltextzugriff (PDF)

Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia

The American journal of gastroenterology, 2021-04, Vol.116 (4), p.675-682

2021

Volltextzugriff (PDF)

The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia

Gastroenterology (New York, N.Y. 1943), 2023-11, Vol.165 (5), p.1168-1179.e6

2023

Volltextzugriff (PDF)

Today’s Mistakes and Tomorrow’s Wisdom in Development and Use of Biomarkers for Barrett’s Esophagus

Visceral medicine, 2022-06, Vol.38 (3), p.173-181

2022

Volltextzugriff (PDF)

Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis

Clinical and translational gastroenterology, 2020-10, Vol.11 (10), p.e00244-e00244

2020

Volltextzugriff (PDF)

Su1268 IDENTIFYING PUTATIVE GENOMIC BIOMARKERS FOR RISK STRATIFICATION IN BARRETT'S ESOPHAGHUS PATIENTS WITH NORMAL HISTOLOGICAL FEATURES

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-717-S-717

2024

Volltextzugriff (PDF)

ERCP in babies: Low risk of post-ERCP pancreatitis – results from a multicentre survey

United European gastroenterology journal, 2020-02, Vol.8 (1), p.77-80

2020

Volltextzugriff (PDF)

Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease

Vaccines (Basel), 2024-07, Vol.12 (7), p.774

2024

Volltextzugriff (PDF)

Mo1149: DEGREE OF CRYPT ATYPIA IS A RISK FACTOR FOR PROGRESSION TO HIGH GRADE DYSPLASIA/ADENOCARCINOMA IN BARRETT'S ESOPHAGUS. A PREVIOUSLY UNREPORTED FINDING

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-714-S-714

2022

Volltextzugriff (PDF)

388 GENOMIC MARKERS FOR ENHANCED RISK STRATIFICATION IN BARRETT'S ESOPHAGHUS PATIENTS WITH LOW GRADE DYSPLASIA

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-87-S-87

2024

Volltextzugriff (PDF)

Degree of crypt atypia correlates with progression to high‐grade dysplasia/adenocarcinoma in non‐dysplastic Barrett's oesophagus

Histopathology, 2023-09, Vol.83 (3), p.406-413

2023

Volltextzugriff (PDF)

372 An Automated, Quantitative Multiplex Immunofluorescence Assay Accurately Risk Stratifies Barrett’s Esophagus Patients With a Community-Based Diagnosis of Low-Grade Dysplasia at a Rate Comparable to Expert Pathologists

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S218-S218

2019

Volltextzugriff (PDF)

371 Evaluation of Additional Spatial and Temporal Information Increases the Overall Accuracy of an Objective Risk Prediction Assay in Patients With Non-Dysplastic Barrett’s Esophagus

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S217-S218

2019

Volltextzugriff (PDF)

695: AN OBJECTIVE, FULLY AUTOMATED BARRETT'S RISK PREDICTION ASSAY OUTPERFORMS MOST PATHOLOGISTS IN RISK STRATIFYING BARRETT'S ESOPHAGUS WITH LOW GRADE DYSPLASIA

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-174-S-174

2022

Volltextzugriff (PDF)

Endoscopic Treatment of Early Barrett’s Adenocarcinoma and Dysplasia: Focus on Submucosal Cancer

Digestion, 2019-01, Vol.99 (4), p.293-300

2019

Volltextzugriff (PDF)

Sa1175: A CLINICALLY APPLICABLE, GENOMIC ASSAY DETECTS PATHOGENIC ALTERATIONS IN BARRETT'S ESOPHAGUS PATIENTS WITH NONDYSPLASTIC TISSUE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-901-S-902

2022

Volltextzugriff (PDF)

Systemic and T cell‐associated responses to SARS‐CoV‐2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS‐CoV‐2

Alimentary pharmacology & therapeutics, 2023-01, Vol.57 (1), p.103-116

2023

Volltextzugriff (PDF)

1085 INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT PROGRESSION IN COMMUNITY-BASED BARRETT'S ESOPHAGUS WITH LOW-GRADE DYSPLASIA: ANALYSIS IN A COMPLETED PROSPECTIVE STUDY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-211-S-212

2020

Volltextzugriff (PDF)

Sa1189 INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT FUTURE PROGRESSION IN NON-DYSPLASTIC BARRETT'S ESOPHAGUS: A SPATIALTEMPORAL ANALYSIS

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-304-S-305

2020

Volltextzugriff (PDF)

High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study

Obesity surgery, 2020-07, Vol.30 (7), p.2659-2666

2020

Volltextzugriff (PDF)

43 TISSUECYPHER OBJECTIVELY RISK STRATIFIES BARRETT'S ESOPHAGUS PATIENTS WITH LOW GRADE DYSPLASIA

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-12-S-12

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Screening for Barrett’s esophagus: Ready for prime time or still hard to swallow?

S386 An Objective Spatialomics Test Standardizes Management Decisions With Potential to Improve Health Outcomes for Barrett’s Esophagus Patients

Risk stratification in Barrett's esophagus patients with diagnoses of indefinite for dysplasia: the definite silver bullet has not (yet) been found

An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus

Feasibility Study Utilizing NanoString's Digital Spatial Profiling (DSP) Technology for Characterizing the Immune Microenvironment in Barrett's Esophagus Formalin-Fixed Paraffin-Embedded Tissues

Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia

The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia

Today’s Mistakes and Tomorrow’s Wisdom in Development and Use of Biomarkers for Barrett’s Esophagus

Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis

Su1268 IDENTIFYING PUTATIVE GENOMIC BIOMARKERS FOR RISK STRATIFICATION IN BARRETT'S ESOPHAGHUS PATIENTS WITH NORMAL HISTOLOGICAL FEATURES

ERCP in babies: Low risk of post-ERCP pancreatitis – results from a multicentre survey

Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease

Mo1149: DEGREE OF CRYPT ATYPIA IS A RISK FACTOR FOR PROGRESSION TO HIGH GRADE DYSPLASIA/ADENOCARCINOMA IN BARRETT'S ESOPHAGUS. A PREVIOUSLY UNREPORTED FINDING

388 GENOMIC MARKERS FOR ENHANCED RISK STRATIFICATION IN BARRETT'S ESOPHAGHUS PATIENTS WITH LOW GRADE DYSPLASIA

Degree of crypt atypia correlates with progression to high‐grade dysplasia/adenocarcinoma in non‐dysplastic Barrett's oesophagus

372 An Automated, Quantitative Multiplex Immunofluorescence Assay Accurately Risk Stratifies Barrett’s Esophagus Patients With a Community-Based Diagnosis of Low-Grade Dysplasia at a Rate Comparable to Expert Pathologists

371 Evaluation of Additional Spatial and Temporal Information Increases the Overall Accuracy of an Objective Risk Prediction Assay in Patients With Non-Dysplastic Barrett’s Esophagus

695: AN OBJECTIVE, FULLY AUTOMATED BARRETT'S RISK PREDICTION ASSAY OUTPERFORMS MOST PATHOLOGISTS IN RISK STRATIFYING BARRETT'S ESOPHAGUS WITH LOW GRADE DYSPLASIA

Endoscopic Treatment of Early Barrett’s Adenocarcinoma and Dysplasia: Focus on Submucosal Cancer

Sa1175: A CLINICALLY APPLICABLE, GENOMIC ASSAY DETECTS PATHOGENIC ALTERATIONS IN BARRETT'S ESOPHAGUS PATIENTS WITH NONDYSPLASTIC TISSUE

Systemic and T cell‐associated responses to SARS‐CoV‐2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS‐CoV‐2

1085 INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT PROGRESSION IN COMMUNITY-BASED BARRETT'S ESOPHAGUS WITH LOW-GRADE DYSPLASIA: ANALYSIS IN A COMPLETED PROSPECTIVE STUDY

Sa1189 INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT FUTURE PROGRESSION IN NON-DYSPLASTIC BARRETT'S ESOPHAGUS: A SPATIALTEMPORAL ANALYSIS

High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study

43 TISSUECYPHER OBJECTIVELY RISK STRATIFIES BARRETT'S ESOPHAGUS PATIENTS WITH LOW GRADE DYSPLASIA

Suchergebnisse filtern